RE:RE:RE:RE:RE:RE:RE:RE:RE:Catalyst SPCEO1 wrote: The many NASH failures may be a blessing in disguise for TH as the analysts covering these stocks desperately need a new name to focus on. And the Liver Therapy Forum is still cranking out a ton of info. But I have to believe the many trial failures are not helping her site much. Nevertheless, she is doing a ton of work on a large number of liver related stocks.
qwerty22 wrote: Just playing devils-advocate for a moment (ok I do it all the time), it looks to me like the US Nash sector is continuing to look depressed. SPs are low, volumes look anemic, I think the general consensus is the run of results at the end of 2018-early 2019 was underwhelming. It doesnt look like we'll be jumping into a red-hot sector. Things may pick up next year, my memory is a slew of new important trial readouts will happen again, including some important combo trials. That may get things moving again but I'm not sure to expect too much from the US in the very near term at least. Having said that it probably cant be worse than Canada. Spceo are you still following the liver forum woman? Is she still pumping out articles regularly?
SPCEO1 wrote: The lack of demand is apparentl and I beleive it reflects the fact that the company is in a "no man's land" between the legay analysts largely not covering it closely and the NASDAQ listing, when we hope new analsyts capable of seeing the value we see in the company's HIV NASH and cancer opportunities. But the stock is pretty close to exiting that no man's land so this lack of demand might be met by an impressive amount of demand from NASH-knowledgeable US investors before too long.
The company has said it will speak to the FDA sometime before the end fo the year and that its phase III test will start around the middle of 2020. I doubt they have spoken with the FDA yet but they gave themselves plenty of time to get that accomplished. I don't know if we will get a press release or not until after everything is finalized with the FDA but I would guess it is unlikely they will tell us much until they have the final word from the FDA. That has been my impression from speaking with them but I could be wrong about that.
I find the early tax loss selling to be unusual and I hope the person doing so does not get burned because there could be a lot happening over the next 30 days that could send the stock higher. But perhaps they bought the stock more than 30 days ago and are now jettisoning the shares that have losses from the past.
scarlet1967 wrote: Tax loss selling usually happens in late December unless some folks selling and wait a full month (you can’t sell and buy back few days later as per CRA so one has to wait the full month) so it’s possible some people are anticipating none of the catalysts mentioned earlier would happen in the next month or so, that would be the only reason for tax loss selling now IMO.
I still think the SP is drifting lower because of lack of demand rather than tax losses which is worrying as if TH’s stock goes below $5 Canadian it will be some force selling as it looses some credit in margin accounts.
It was mentioned the company might not inform the market re the communication with FDA, I really hope they do as lack of new information has dried up the demand thus lower SP so we do need some good news ASAP to stop/reverse the constantly lower valuation almost on daily basis.
Devil advocate lets play it here. Maybe just maybe the fanboys can see if nash has a failure and th is amongst the rest some well more financially set. So what's the scenario then what happens to this stock then. Anyone? Or is it gonna be dead silence again, I do look at the other side of the coin.